Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 10Breast Neoplasms 9Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Adenomatous Polyposis Coli 4Sarcoma 3Glioblastoma 3Central Nervous System Neoplasms 3Paranasal Sinus Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Breast Carcinoma In Situ 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Stomatitis 1Smoldering Multiple Myeloma 1Smoking 1Recurrence 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Precancerous Conditions 1

Interventions

Darbepoetin alfa 2piperine 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1Whole-Body Irradiation 1Urination 1Therapeutics 1Sucrose 1Rituximab 1Phenytoin 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Mycophenolic Acid 1Morphine 1Methotrexate 1Methadone 1Metformin 1KW-2478 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Fentanyl 1Fatty Acids, Omega-3 1Epoetin Alfa 1Early Intervention, Educational 1Cyclosporine 1Curcumin 1Celecoxib 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Monoclonal Gammopathy of Undetermined Significance × Celecoxib × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡